TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations

Area of Science:

• Molecular Oncology
• Cancer Signaling Pathways

Background:

• Pancreatic ductal adenocarcinoma (PDAC) exhibits near-universal KRAS mutations and resistance to treatment, often involving NF-κB transcription factors driven by the IRAK/IKK cascade.
• Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a role in inflammatory responses and cell signaling.

Purpose of the Study:

• To investigate the role of IRAK4 in MAPK pathway activation in KRAS-mutant PDAC.
• To identify key kinases downstream of IRAK4 that regulate both MAPK and NF-κB signaling in PDAC.
• To evaluate TPL2 as a therapeutic target in PDAC, alone and in combination with chemotherapy.

Main Methods:

• Reverse-phase protein array (RPPA) and RNA sequencing were employed to analyze signaling pathways.
• IRAK4 ablation and TPL2 inhibition were used to assess their impact on cell transformation and signaling.
• Analysis of The Cancer Genome Atlas (TCGA) data identified specific MAP3K8 mutations.

Main Results:

• IRAK4 ablation blocked RAS-induced transformation, and mutant KRAS activated an IL-1β autocrine loop that engaged IRAK4 and the MAPK pathway.
• TPL2 (MAP3K8) was identified as the essential kinase downstream of IRAK4, mediating both MAPK and NF-κB activation, and its inhibition suppressed KRAS-mutant cell growth.
• TPL2 inhibition synergized with chemotherapy to reduce PDAC growth in vivo, and specific MAP3K8 mutations conferring sensitivity to TPL2 inhibition were identified.

Conclusions:

• TPL2 is a critical mediator of oncogenic signaling in KRAS-mutant PDAC, linking inflammatory and MAPK pathways.
• TPL2 inhibition represents a promising therapeutic strategy for PDAC, particularly in combination with chemotherapy or in tumors with specific MAP3K8 mutations.
• The study highlights the need for developing TPL2 inhibitors for clinical application in RAS- and MAP3K8-mutant cancers.